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Abstract
Background: Temporal lobe epilepsy (TLE) with hippocampal sclerosis (HS) is a common pharmaco-resistant
epilepsy referred for adult epilepsy surgery. Though associated with prolonged febrile seizures (FS) in childhood, the
neurobiological basis for this relationship is not fully understood and currently no preventive or curative therapies
are available. DNA methylation, an epigenetic mechanism catalyzed by DNA methyltransferases (DNMTs), potentially
plays a pivotal role in epileptogenesis associated with FS. In an attempt to start exploring this notion, the present
cross-sectional pilot study investigated whether global DNA methylation levels (5-mC and 5-hmC markers) and
DNMT isoforms (DNMT1, DNMT3a1, and DNMT3a2) expression would be different in hippocampal and neocortical
tissues between controls and TLE patients with or without a history of FS.
Results: We found that global DNA methylation levels and DNMT3a2 isoform expression were lower in the
hippocampus for all TLE groups when compared to control patients, with a more significant decrease amongst the
TLE groups with a history of FS. Interestingly, we showed that DNMT3a1 expression was severely diminished in the
hippocampus of TLE patients with a history of FS in comparison with control and other TLE groups. In the
neocortex, we found a higher expression of DNMT1 and DNMT3a1 as well as increased levels of global DNA
methylation for all TLE patients compared to controls.
Conclusion: Together, the findings of this descriptive cross-sectional pilot study demonstrated brain region-specific
changes in DNMT1 and DNMT3a isoform expression as well as global DNA methylation levels in human TLE with or
without a history of FS. They highlighted a specific implication of DNMT3a isoforms in TLE after FS. Therefore,
longitudinal studies that aim at targeting DNMT3a isoforms to evaluate the potential causal relationship between
FS and TLE or treatment of FS-induced epileptogenesis seem warranted.
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Introduction
Temporal lobe epilepsy (TLE) is the most common type
of focal epilepsy in adulthood. TLE is drug-resistant in
about one third of patients, necessitating surgical resec-
tion of the epileptogenic focus as a curative treatment
option [1]. Drug-resistant TLE is frequently associated
with hippocampal sclerosis (HS) as the major patho-
logical entity. In general, HS is histopathologically char-
acterized by astrogliosis and neuronal loss, most
prominently in the cornu ammonis (CA) 1 and CA3 re-
gions and in the dentate gyrus (DG) of the hippocampus.
In addition, 50% of the patients with HS display various
degrees of granule cell dispersion in the DG [2]. Typical
febrile seizures (FS) are fever-triggered convulsions, af-
fecting 2–14% of children between the age of 6 months
and 5 years. FS have been linked to the development of
subsequent TLE with HS in 30–40% of the cases [3].
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Little is known about the pathophysiological mecha-
nisms of TLE, especially after FS. In a well-characterized
rodent model of FS, i.e., that of neonatal hyperthermia,
FS have been shown to result in enhanced hippocampal
excitability and consequently an increase in epileptic sei-
zures [4]. Molecular and cellular changes have been
demonstrated and correlated to the generation of this
enhanced excitability (for review, see [5]). Identifying the
mechanisms that regulate the transcription of genes that
mediate these alterations may open new perspectives for
the treatment of drug-resistant epilepsy or for the pre-
vention of FS-induced epileptogenesis.
Epigenetic mechanisms, which refer to inherited
and acquired changes in gene transcription that oc-
curred without modification in the DNA sequence,
have been proposed to play a prominent role in vari-
ous neurological disorders, including epilepsy [6].
They are involved in multiple aspects of brain func-
tions and associated behaviors, e.g., impacting on
neuronal development, neuronal and synaptic plasti-
city, and memory [7]. DNA methylation, a key epi-
genetic modification implicated in the regulation of
gene transcription, has been shown to be highly dy-
namic in the adult brain, e.g., in the hippocampus in
response to neural activity [8], and it is thought to be
crucial for brain homeostasis. DNA methylation is the
covalent modification of cytosine residues on CpG di-
nucleotides to form 5-methylcytosine (5-mC) that is
catalyzed by DNA methyltransferases (DNMTs) [9]. 5-
Hydroxymethylcytosine (5-hmC) is the oxidative vari-
ant of 5-mC and is generated during a reaction cata-
lyzed by ten-eleven translocation enzymes [10]. The
exact function of 5-hmC is still not fully elucidated,
but evidence indicates that 5-hmC marks can regulate
gene expression by driving DNA demethylation [11].
Moreover, 5-hmC has been shown to be highly abun-
dant in the brain compared to other tissues [12].
Various types of DNMTs have been reported in-
cluding DNMT1, DNMT3a, and DNMT3b. DNMT1,
referred to as maintenance DNMT, conserves DNA
methylation after every cellular DNA replication cycle,
whereas DNMT3a and DNMT3b promote de novo
DNA methylation. While more than 30 enzymatically
active isoforms of DNMT3b exist [13], two isoforms
of DNMT1 [14] and DNMT3a [15] have been de-
scribed. For DNMT3a, these include the full-length
isoform, known as DNMT3a1, and the shorter one,
called DNMT3a2. DNMT3a2 lacks the 219 amino
acids at the N-terminal part of DNMT3a1 and is
transcribed from an alternative promoter in the sixth
intron of the DNMT3a gene [15].
DNMTs have been shown to play an important role
during brain development as inactivation of Dnmt1 in
mouse leads to embryonic lethality [16] and DMNT3a/
3b knockout mice die within few weeks postnatally [17].
The high expression of DNMT1, DNMT3a2, and
DNMT3b in early stages of neurogenesis [15, 18, 19] de-
creases upon differentiation, while DNMT3a1 protein
levels increase postnatally [19, 20]. Over the lifespan, the
abundance of DNMT3a1 declines following synaptogen-
esis in neurons with very low levels during aging [19].
Remarkably, all the DNMT isoforms are still expressed
in adult brain with DNMT1 and DNMT3a1 being more
abundant than DNMT3b and DNMT3a2 [15, 18, 21,
22]. DNMT proteins were reported to be strongly
expressed in neuronal as compared to glial cells [23].
In addition to their role during development, studies
have demonstrated the functional importance of
DNMTs and dynamic methylation in the adult brain,
e.g., in learning and memory, synaptic plasticity, and be-
havior [24–28]. Recent evidences suggest that aberrant
DNA methylation and expression of DNMTs may be
causal or contributing factors in a variety of neurological
disorders including epilepsies [26]. For example, preclin-
ical data have shown altered DNA methylation patterns
and DNMT activity in rodent models of status epilepti-
cus and chronic TLE [29–31] as well as in human TLE
[32–34]. In addition, the expression of DNMT1 and
DNMT3a was shown to be increased in the neocortex of
TLE patients [35].
Based on these findings, one could speculate that
DNA methylation represents a crucial event triggered by
FS, which leaves a permanent imprint on gene expres-
sion and physiological processes, thereby mediating epi-
leptogenesis responsible for the development of TLE
later in life. In order to start exploring this notion at a
descriptive level, the present pilot study aimed to assess
the expression of DNMT1 and DNMT3a isoforms and
the level of global DNA (hydroxy)methylation in the
pathogenesis of FS followed by TLE. We thereby tested
the hypothesis that hippocampal and neocortical expres-
sion of DNMT1 and DNMT3a isoforms, as well as the
levels of markers of global DNA methylation and hydro-
xymethylation (5-mC and 5-hmC, respectively), would
be different between controls and TLE patients with or
without a history of FS.
Results
Expression of DNMT1 in the neocortex and hippocampus
of TLE patients
We first analyzed the expression levels of the two
DNMT1 protein isoforms by Western blot using tissue
from the hippocampus (Fig. 1a) and temporal neocortex
(Fig. 1c) of controls (CTRL) and three TLE patient
groups (HS−, HS+, and HS+FS+). The HS+ group was in-
cluded in the analysis to control for the possible influ-
ence of HS in the HS+FS+ group. The two isoforms of
DNMT1 have a similar molecular weight of 183 kDa and
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184 kDa, which urged us to quantify both forms together
(here referred to as DNMT1). For normalization, we
used GAPDH as a control for protein loading. As shown
in Additional file 1A and B, the expression of GAPDH
was not different between control and TLE groups in
both types of tissues studied. Western blot analysis for
DNMT1 revealed the expected band size for DNMT1, as
previously described [36], with two extra bands at lower
molecular weights (≈ 140 and 60 kDa). In the hippocam-
pus, we found a significantly elevated expression of
DNMT1 in HS− subjects when compared to the CTRL
group and to the other epileptic groups (Fig. 1b). In the
neocortex, DNMT1 expression was higher in all epilep-
tics groups compared to the CTRL group but not at a
statistically significant level (Fig. 1d). As expression pro-
files may be influenced by degradation (in relation to in-
creasing post-mortem intervals), we furthermore tested
in mice whether the post-mortem interval influenced the
expression levels of the DNMT1. For that purpose, we
experimentally varied the post-mortem interval in mice
and analyzed the expression of the mouse Dnmt1 in the
hippocampus and the neocortex by Western blot. As
shown in Additional file 2, Dnmt1 expression did not
significantly change up to 24 h post-mortem delay at
room temperature neither in the hippocampus (Add-
itional file 2A, B), nor in the temporal neocortex (Add-
itional file 2C, D). Similarly, human DNMT1 expression
levels did not correlate with post-mortem interval for
human hippocampus and neocortex (Additional file 6,
PMI correlation).
Differential expression of DNMT3a isoforms in the human
TLE hippocampus and neocortex
As for DNMT1, we analyzed the expression of
DNMT3a1 and DNMT3a2 protein isoforms by Western
blot in the hippocampus (Fig. 2a) and the temporal neo-
cortex (Fig. 2d) of the same CTRL and TLE groups.
GAPDH levels were not significantly different in both
tissues studied between CTRL and epilepsy groups
(Additional file 1C, D). The blots showed bands of ex-
pected size for both isoforms (130 kDa for DNMT3a1
and 81 kDa for DNMT3a2), as previously described [37],
Fig. 1 DNMT1 protein expression in the TLE hippocampus (a, b) and neocortex (c, d). a, c Representative Western blot showing DNMT1 (green)
in the TLE hippocampus (a) and neocortex (c) compared to controls. GAPDH (red) was used as a protein loading control. b, d Graph showing
semi-quantification of the Western blots for hippocampus (b) and neocortex (d). DNMT1 expression was normalized to GAPDH expression. Error
bars show SEM. ***p < 0.001 for significant difference to CTRL. ††p < 0.01 and †††p < 0.001 for significant difference to HS− group. MM =molecular
weight marker; CTRL = control; HS− = TLE without HS; HS+ = TLE with HS; HS+FS+ = TLE with HS and FS
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with two extra bands at lower molecular weights (≈ 45
and 60 kDa). In the hippocampus, we demonstrated that
the expression of DNMT3a1 and DNMT3a2 was statisti-
cally significantly diminished in HS+FS+ subjects com-
pared to CTRL and other TLE groups (Fig. 2b). In order
to confirm these findings at the mRNA level, we per-
formed qRT-PCR (Fig. 2c) and obtained the same results
for DNMT3a1. On the other hand, we found that all
TLE groups displayed a significant decrease of
DNMT3a2 transcript expression compared to CTRL
(Fig. 2c). Within the TLE groups, patients with FS
showed a significant decrease compared to HS− but not
to HS+ group (Fig. 2c). By contrast, in the neocortex, the
protein (Fig. 2e) and mRNA transcript (Fig. 2f) levels of
DNMT3a1 were significantly increased for all TLE
groups compared to the CTRL. No changes in the ex-
pression of the DNMT3a2 protein and transcript were
found in the neocortex (Fig. 2e, f).
In order to exclude the possibility that the reduced
DNMT3a levels were the results of degradation, the sta-
bility of murine Dnmt3a isoform’ protein levels with in-
creasing post-mortem delay was confirmed as described
for Dnmt1 (Additional file 3). In addition, human
DNMT3 isoform expression did not correlate with post-
mortem interval neither within the hippocampus nor in
the neocortex (Additional file 6, PMI correlation).
Decreased expression of DNMT3a2 isoform in the TLE
dentate gyrus of the hippocampus
In order to further explore whether the decrease in
DNMT3a isoforms in TLE hippocampus were specific for
different hippocampal sub-regions, we performed immuno-
histochemistry on the same hippocampal samples using the
same antibody used in Western blot experiments. As this
antibody recognizes both DNMT3a isoforms, we quantified
the expression of both isoforms together (denoted as
DNMT3a) and could not specifically analyze DNMT3a1 or
DNMT3a2 isoforms using immunohistochemistry. The ex-
pression pattern of DNMT3a in the DG is presented in
Fig. 3a. The integrated density of DNMT3a immunoreactiv-
ity in the DG showed a statistically non-significant decrease
in global DNMT3a levels in HS− and HS+FS+ compared to
CTRL, whereas the area containing DNMT3a-positive cells
showed a statistically significant decrease in HS+ and
HS+FS+ groups compared to CTRL (Fig. 3c).
To explore to which extent the decrease in DNMT3a2
expression level in the hippocampus (Fig. 2) was medi-
ated via the DG, we performed in situ hybridization with
DNMT3a2 mRNA probe (Fig. 4a). Quantifications ana-
lysis revealed that all TLE groups displayed a significant
decrease of DNMT3a2 integrated density and the area
expressing DNMT3a2 mRNA compared to CTRL
(Fig. 4b, c). Within the TLE groups, patients with FS
Fig. 2. DNMT3a isoforms expression in the TLE hippocampus (a–c) and neocortex (d–f). a, d Representative Western blot showing DNMT3a
isoforms (green) in the TLE hippocampus (a) and neocortex (d) compared to control. GAPDH (red) was used as a protein loading control. b, e
Graph showing semi-quantification of the Western blots for the hippocampus (b) and neocortex (e). DNMT3a isoforms expression was
normalized to GAPDH expression. c, f Real-time PCR validation of Western blots results for hippocampus (c) and neocortex (f). Error bars show
SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 for significant difference to CTRL. ††p < 0.01 and †††p < 0.001 for significant difference to HS− group.
¥p < 0.05 and ¥¥p < 0.01 for significant difference to HS+ group. MM =molecular weight marker; CTRL = control; HS− = TLE without HS; HS+ = TLE
with HS; HS+FS+ = TLE with HS and FS
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showed a significant decrease compared to HS− and HS+
groups (Fig. 4c).
For these experiments as well, the post-mortem inter-
val did not correlate with the expression of DNMT3a
isoforms (Additional file 6, PMI correlation).
Differences in global 5-mC and 5-hmC levels following
TLE
In order to analyze whether the changes in DNMT1
and DNMT3a expression may have impacted on the
global levels of DNA methylation and hydroxymethyla-
tion, we analyzed 5-mC and 5-hmC levels by immuno-
histochemistry in the same hippocampal (Fig. 5) and
neocortical tissue samples (Fig. 6). Semi-quantitative
image analyses revealed a significant decrease in inte-
grated density of 5-mc and 5-hmc in all TLE groups
compared to CTRL (Fig. 5b, e). Moreover, 5-mC inte-
grated density was significantly decreased in HS+FS+
group compared to HS− and HS+ ones (Fig. 5b). The
area stained for 5-mc and 5-hmc was significantly de-
creased in the DG of all TLE groups compared to
CTRL (Fig. 5c, f). On the contrary, in the neocortex, 5-
mC integrated density was significantly increased in all
TLE patients compared to CTRL (Fig. 6b), yet no sig-
nificant difference in 5-hmC was observed (Fig. 6c, d).
Correlation analyses did not reveal any statistically sig-
nificant association between the levels of 5-mC and 5-
hMC and the post-mortem interval (Additional file 6,
PMI correlation).
Fig. 3 DNMT3a immunoreactivity in the hippocampal DG. a Representative pictures of DNMT3a staining in the hippocampal DG of TLE patients
and controls. Scale bars represent 100 μm. b ImageJ quantification of the integrated density of DNMT3a staining. c Stereological quantification of
the area expressing DNMT3a. Error bars show SEM in b and CE in c. **p < 0.01 for significant difference to CTRL. †p < 0.05 and ††p < 0.01 for
significant difference to HS− group. ¥ p < 0.05 for significant difference to HS+ group. CTRL = control; HS− = TLE without HS; HS+ = TLE with HS;
HS+FS+ = TLE with HS and FS.
Fig. 4 DNMT3a2 transcript localization in the DG of the hippocampus. a Representative pictures of DNMT3a2 in situ hybridization in the
hippocampal DG of TLE patients and controls. Scale bars represent 100 μm. b ImageJ quantification of the integrated density of DNMT3a2
reactivity. c Stereological quantification of the area expressing DNMT3a2. Error bars show SEM for ImageJ and CE for stereology. **p < 0.01 and
***p < 0.001 for significant difference to CTRL. †††p < 0.01 for significant difference to HS−. ¥¥¥p < 0.001 for significant difference to HS+. CTRL =
control; HS− = TLE without HS; HS+ = TLE with HS; HS+FS+ = TLE with HS and FS.
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Discussion
The main aim of the present cross-sectional pilot study
was to make a first step in the exploration of the pos-
sible involvement of DNA methylation and DNMT iso-
forms in the pathophysiology of TLE with or without a
history of FS. To our knowledge, this is the first to inves-
tigate DNMT isoforms and global DNA (hydroxy)-
methylation profiles in TLE using specimen from
surgically treated TLE patients with HS and a history of
FS. In the neocortex, we found an increase of DNMT1
and DNMT3a1 expression and global DNA methylation
levels for all TLE groups compared to the CTRL. By
contrast, we showed that DNMT3a2, global DNA
methylation, and hydroxymethylation levels were pro-
foundly lower in the hippocampus, specifically in the
DG, for all TLE groups compared to the CTRL, with a
more significant decrease amongst the TLE groups with
a history of FS. Remarkably, we demonstrated that
DNMT3a1 isoform expression was specifically decreased
in the hippocampus of TLE patients with a history of FS
compared to epileptic groups without FS and CTRL. A
summary of the main findings of this study is presented
in Table 1. Together, these results provide the first evi-
dence to support the hypothesis that DNA (hydroxy)-
methylation, DNMT1, and DNMT3a isoforms may be
involved in a brain region-specific manner to mediate
differential epileptogenesis in TLE with or without a his-
tory of FS.
Our findings in the neocortex are consistent with a
previous study from Zhu et al., showing that DNMT1
and DNMT3a protein expression levels were increased
in human neocortex from TLE patients without HS [35].
In line with the results of our study of the hippocampus,
previous studies on animal models of status epilepticus
have demonstrated a decreased Dnmt3a transcript ex-
pression and global DNA methylation [31] as well as
genome-wide prominent hypomethylation of gene pro-
moters in the hippocampus of cases with epilepsy [29].
In contrast to our results, global DNA methylation pat-
terns were shown to be increased in the hippocampus of
a kindling rat model of TLE [33] and in chronic rat epi-
lepsy induced by pilocarpine [30]. Moreover, in the hu-
man TLE hippocampus, Kobow et al. found increased
methylation of the Reelin promoter associated with
granule cell dispersion in the hippocampus [34] and
Miller-Delaney and colleagues reported genome-wide
hypermethylation in relation to HS [32]. Recently, in a
rat model of FS, the expression of Dmnt1 mRNA and
protein was found to be increased in the adult hippo-
campus of animals that experienced FS at post-natal day
Fig. 5 Global 5-mC and 5-hmc patterns in the hippocampal DG. a, d Representative pictures of 5-mC staining (a) and 5-hmc staining (d) in the
hippocampal DG of TLE patients and controls. Scale bars represent 100 μm. b, e ImageJ quantification of the integrated density of 5-mc staining
(b) and 5-hmc staining (e). Error bars show SEM. c, f Stereological quantification of the area expressing 5-mC staining (c) and 5-hmc staining (f).
Error bars show CE. n = 3–7 per group. *p < 0.05 and ***p < 0.001 for significant difference to CTRL. ††p < 0.01 and †††p < 0.001 for significant
difference to HS− group. ¥¥p < 0.01 for significant difference to HS+. CTRL = control; HS− = TLE without HS; HS+ = TLE with HS; HS+FS+ = TLE with
HS and FS
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10, while DNMT3a expression did not change [38]. The
dissimilarities between our results and other studies might
be explained by the different experimental setup and time
points (acute vs chronic) used, but further studies are re-
quired to prove these possibilities. To summarize, our ac-
tual work with prior reports concluded that DNA
methylation and DNMTs might play a major role in TLE.
However, it also demonstrates that DNA methylation as
well as DNMT1 and DNMT3a isoform profiles appear to
display brain region-specific patterns potentially depending
on the etiology of TLE, the stage of the disease develop-
ment, and ongoing pathology. This hypothesis is further
Fig. 6 Global 5-mC and 5-hmc patterns in the neocortex. a, c Representative pictures of 5-mC staining (a) and 5-hmc staining (c) in the
neocortex of TLE patients and controls. Scale bars represent 100 μm. b, d ImageJ quantification of the integrated density of 5-mc staining (b) and
5-hmc staining (d) in the neocortex. n = 6–8 per group. Error bars show SEM. **p < 0.01 and ***p < 0.001 for significant difference to CTRL.
CTRL = control; HS− = TLE without HS; HS+ = TLE with HS; HS+FS+ = TLE with HS and FS
Table 1 Summary of the main findings described in this study
Tissue Variables measured Methods Groups comparison Effect
Neocortex DNMT1 WB All TLE groups vs CTRL ↑
Neocortex DNMT3a1
DNMT3a1
WB, qRT-PCR All TLE groups vs CTRL ↑
Neocortex 5-mC IHC All TLE groups vs CTRL ↑
Hippocampus DNMT1 WB HS− vs CTRL ↑
Hippocampus DNMT3a2 qRT-PCR, ISH All TLE groups vs CTRL ↓




Hippocampus 5-mC, 5hmC IHC All TLE groups vs CTRL ↓
Hippocampus DNMT3a1
DNMT3a1




WB Western blot, TLE temporal lobe epilepsy, CTRL control, qRT-PCR quantitative reverse transcription polymerase chain reaction, IHC immunohistochemistry, ISH
in situ hybridization, FS febrile seizures, HS hippocampal sclerosis
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supported by recent work showing dissimilarities in gen-
ome-wide methylation changes in animal models and hu-
man epilepsies with different etiologies [32, 39, 40]. These
results are also in accordance with previous studies showing
dissociable roles for DNMT1 and DNMT3a in learning and
memory, adult behavior, and synaptic plasticity [25, 26, 41,
42].
A major finding in the present study was that the ex-
pression of DNMT3a1 and DNMT3a2 and the levels of
global DNA methylation were severely decreased in the
hippocampus after FS. Molecular and cellular changes
have been well-documented to contribute to FS-induced
epileptogenesis. For example, an animal model of FS and
human TLE has been associated with increased hippo-
campal neurogenesis [43, 44]. Moreover, FS have been
linked to several comorbidities such as memory impair-
ments [45, 46]. In this regard, one could speculate that
FS-induced changes in DNA methylation may transiently
or persistently affect gene expression patterns respon-
sible for key phases of the epileptogenesis process and
associated comorbidities. In fact, it was demonstrated
that DNMT3a play a critical role in adult neurogenesis
with DNMT3a deficiency leading to enhanced prolifera-
tion of postnatal neuronal stem cells, impaired differen-
tiation to neurons, and increased astrogliogenesis and
oligodendrogenesis [47, 48]. In addition, Oliveira and
colleagues have reported that DNMT3a2 was an en-
dogenous player in memory formation [27, 28]. Along
these lines, cortical infusion of DNMT inhibitors after
the establishment of short-term memory has been
shown to impair memory consolidation and formation
of long-term memory [49]. Therefore, it will be interest-
ing to further investigate (and experimentally test) the
possible interpretation of our results, i.e., that decreased
expression of DNA methylation, DNMT3a1, and
DNMT3a2 could contribute to increased proliferation of
newborn cells, astrogliosis, and memory impairment ob-
served in TLE after FS. Clearly, also the cellular mecha-
nisms by which DNMT3a isoforms and DNA
methylation contribute to gene expression and cellular
changes in FS-induced epileptogenesis need further in-
vestigation in rodent models of FS and in human TLE.
There are some limitations of the present study. The
first one is that our investigation is a pilot study that
was performed using a small sample size. However, the
post hoc power calculation demonstrated that the statis-
tically significant results obtained were supported by a
power higher than 80%. Another constraint is the lack of
age- and gender-matched groups. To circumvent that
issue, we included age and gender as confounding fac-
tors in the statistical analysis. Moreover, because of the
cross-sectional design of the study, we were not able to
disentangle whether the observed epigenetic changes are
the cause or the consequence of TLE development.
Therefore, our main findings should be replicated using
a larger cohort matched for age and gender and with a
longitudinal design to test for causality.
Another caveat is that post-mortem controls may con-
tain autopsy delay that alters the expression of DNMTs
and DNA methylation profiles. The simulation of the
post-mortem delay in our murine experiment showed
that Dnmt1 and Dnmt3a isoform’ proteins levels were
stable until 24 h after death. Regarding DNA (hydroxy)-
methylation, it has been shown that 5-mC and 5-hmC
are stable for more than 48 h post-mortem in human,
pig, and mouse brain [50]. Of note, the longer post-mor-
tem interval of our study is 42 h. In addition, correla-
tions analysis between DNMT isoform expressions, 5-
mC and 5-hmC levels, and post-mortem interval did not
show statistically significant relationship. Together, these
indications suggest that the post-mortem delay most
likely did not influence the results of our study; however,
we could not completely exclude a potential effect.
The use of whole tissue for Western blot and qPCR
analyses did not allow to distinguish differences in
DNMT isoform expression between hippocampal sub-
field and cell types (e.g., glia and neurons). Future stud-
ies using cell sorting or laser capture microdissected
tissues may be able to feature cell type- and subregion-
specific epigenetic changes that occur in TLE with or
without FS history.
Another important limitation is the measurements of
global 5-mC and 5-hmC levels that are unable to specify
where in the genome methylation alterations have oc-
curred. A large number of genes might be involved in
the development of TLE, each of them is likely to exhibit
unique changes in methylation patterns, and depending
on the direction of those changes, effects could be
washed out in a global assessment. Therefore, future
studies investigating gene-specific methylation profiles
and gene expression are needed.
Finally, the influence of antiepileptic drugs on DNA
methylation status should be taken into consideration.
Notably, the effects of antiepileptic drugs on epigenetic
factors are not fully understood (for review, see [51]). In
this study, long-term treatment of all patients with a
combination of several antiepileptic drugs was used be-
fore surgery resections and we could not exclude any
direct or indirect effect of these drugs on DNMT expres-
sion and global (hydroxy)methylation patterns. Future
studies using animal models of TLE should be con-
ducted to unravel the potential influence of antiepileptic
drugs on DNA methylation.
Conclusion
In summary, the findings of our descriptive cross-sectional
pilot study demonstrated a brain region-specific different
pattern of DNMT1 and DNMT3a isoform expression, as
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well as DNA methylation and hydroxymethylation levels in
TLE patients with or without a history of FS. Our results
specifically suggest a potential involvement of DNMT3a
isoforms in FS-induced epileptogenesis. Therefore,
DNMT3a isoforms represent interesting targets for fur-
ther experimental studies to explore the pathophysi-
ology of TLE with different etiologies and to investigate
the causality between FS and TLE. Clearly, the assumed
correlation between neuronal hyperexcitability after
FS, DNA methylation, and DNMTs needs further
study as understanding the exact pathophysiological
mechanisms may contribute to the identification of
disease biomarkers and new treatment strategies to




Human hippocampi and neocortices were collected at
Maastricht University Medical Center (MUMC) as previ-
ously described [52]. In total, 22 TLE patients were in-
cluded, of which 14 did not show any signs of HS (HS−),
10 had the diagnostic of HS (HS+), and 13 had HS with
a history of FS in childhood (HS+FS+). Patient demo-
graphics are presented in Table 2.
Human control tissue samples (CTRL, n = 10) were
obtained from autopsy. These control patients died of
causes not related to a known neurological disease.
Average autopsy delay was 16.7 ± 3.8 h (Table 2).
A detailed description of the samples that were used for
the different analyses is presented in the Additional file 4.
The sample size of our study is within the range of
other studies that analyzed epigenetic mechanism in hu-
man TLE samples [32, 34, 35].
Western blot
Frozen human hippocampus (containing all hippocampal
subregions) and neocortex tissues were homogenized in
lysis buffer (50mM Tris-HCl (pH 7.5), 0.01M phosphate-
buffered saline (PBS), 1% Igepal, 0.1% Triton X-100, 1 mM
EDTA, 1mM EGTA, and protease inhibitors cocktail
(Complete, Roche) using a Mini-Beadbeater (GlenMills).
Lysates were incubated on ice for 30min and subse-
quently clarified by centrifugation at 16,000×g for 20min
at 4 °C. Protein concentrations were determined using the
DC protein assay (BioRad). Total proteins (50 μg per lane)
were separated using a 6 or 8% SDS-PAGE for DNMT1
and DNMT3a, respectively. Each sample was run in tripli-
cate. Proteins were subsequently transferred to a nitrocel-
lulose membrane (Merck Millipore) for 16 h at 90mA.
After 5min washing in PBS and 1 h blocking in Odyssey
Blocking buffer (LI-COR) diluted 1:2 in PBS, the mem-
branes were incubated for 1 h at room temperature with
primary antibodies diluted in Odyssey blocking buffer-
PBS 1:2 (rabbit anti-DNMT1, sc-20701, Santa Cruz, 1:200;
rabbit anti-DNMT3a, sc-20703, Santa Cruz, 1:500; mouse
anti-GAPDH, 10R-G109A, Fitzgerald, 1:2,000,000). Mem-
branes were washed once in PBS-0.1% Tween 20 (PBS-T)
and twice in PBS for 10min each and subsequently incu-
bated for 1 h at room temperature with the secondary
antibodies diluted in Odyssey Blocking buffer-PBS 1:2
(donkey anti-mouse IRDye 670 and goat anti-rabbit IRDye
800, LI-COR, 1:10,000). After three washings of 10min
(PBS-T, PBS, PBS), immunoreactive protein bands were vi-
sualized by an Odyssey Infrared Imaging System (Li-COR).
Immunoblots were analyzed with ImageJ software.
Relative pixel intensities were measured, and the back-
ground signal was subtracted. DNMT1 and DNMT3a
isoform intensities were corrected by their respective
GAPDH expression (relative protein levels).
The validations of DNMT1 and DNMT3a antibodies
are described by He et al. [36] and Challen et al. [37],
respectively.
qRT-PCR
Total RNA was isolated from frozen human hippocampi
and neocortices using the TRIzol reagent (Invitrogen)
following the manufacturer’s instructions. RNA was
quantified on a NanoDrop 1000 spectrophotometer
(NanoDrop Technologies). One microgram of total RNA
was converted into first-strand cDNA with oligo(dT)
primers using RevertAid First Strand cDNA Synthesis
Kit (Thermo Scientific) as described by the manufac-
turer. qPCR experiments were performed using the
Roche 480 LightCycler (Roche Applied Science) with
SensiMix SYBR Hi-ROX (Bioline) and specific primers
listed in Additional file 5. Minus reverse transcription
and non-template controls were used to control for gen-
omic DNA and cross-well contamination, respectively.
All samples were run in triplicates, and triplicates dis-
cordant in Cq by more than 0.5 cycles were excluded
from the analysis. For normalization of mRNA expres-
sion, RefFinder was used to find the most stable refer-
ence gene among YWHAZ, RPL13a, TBP, and NSE. For
hippocampus, the relative abundance of mRNAs was
standardized with the geometric mean of TBP/NSE
mRNA, as previously reported [53], while for the neo-
cortex, RPL13a and TBP were used. Mean normalized
expression was calculated by the Pfaffl method that ac-
counts for amplification efficiencies.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissues were cut at
5 μm on the microtome (Leica). Sections were trans-
ferred onto SuperFrost Plus slides (VWR) and dried
overnight at 37 °C. Slices were deparaffinized and subse-
quently subjected to antigen retrieval in 0.01M citrate
buffer pH 6 for 20min at 95 °C. After cooling down at
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Table 2 Clinical characteristics of TLE patients and post-mortem controls
Controls Gender Age (years) PMI (h) Cause of death Resection side
C1302 Male 62 20 Sepsis Right
C1303 Male 66 39 Heart failure Right
C1304 Male 76 14 Sepsis Left
C1401 Male 80 22 Heart failure Right
C1402 Male 66 14 Sepsis Right
C1403 Male 61 19 Heart failure Right
C1404 Female 84 13 Abdominal carcinoma Right
C1405 Female 64 42 COPD Right
C1406 Female 85 17 Lung carcinoma Right
C1407 Male 83 12 Heart failure Right
TLE patients Gender Age at surgery (years) Age of onset (years) Duration Pathology Antiepileptic drugs
E1011 Male 58 53 5 HS- VPA, CBZ, LTG, LEV
E1013 Female 51 24 27 HS- LEV, CBZ, LTG
E1016 Male 37 31 6 HS- LEV, VPA, CBZ, LTG
E1107 Female 60 17 43 HS- LTG, CBZ, LEV, CLB
E1204 Female 40 16 24 HS- PHT, DZP, OXC, CLZ
E1205 Male 20 N/A N/A HS- N/A
E1206 Male 47 31 16 HS- CLB, OXC, LEV
E1207 Male 29 20 9 HS- OXC, LEV
E1214 Female 39 30 9 HS- LTG, CBZ
E1302 Female 21 20 1 HS- LEV, LAC
E1306 Female 59 7 52 HS- CBZ, CLB
E1319 Female 41 27 14 HS- LEV, CBZ, CLB
E1402 Female 21 1 20 HS- CLE, LEV
E1404 Male 19 8 8 HS- CBZ, CLZ, LEV
E1009 Female 39 4 35 HS+ DZP, CLB, LEV, OXC
E1018 Male 63 2.5 60.5 HS+ CBZ, CLB, PHT, CLZ
E1019 Female 43 3 40 HS+ LTG, CLZ, DZP, LEV, CLB
E1103 Female 58 54 4 HS+ LTG, LEV, OXC, CBZ
E1104 Male 47 3 44 HS+ LEV, PHT
E1217 Male 54 17 37 HS+ FLU, LTG, MET, ZOP
E1218 Male 28 4 24 HS+ CBZ, LTG
E1312 Female 23 19 4 HS+ MDZ
E1318 Female 47 11 36 HS+ LTG, CLB, TMP, VPA
E1407 Male 55 10 45 HS+ MDZ, CBZ, CLB, LEV
E0109 Male 48 30 18 HS+FS+ LTG, CLB, TPM
E0705 Female 23 6 16 HS+FS+ LEV, LTG, CLB
E0707 Female 59 N/A N/A HS+FS+ OXC, CLB, LEV
E1014 Female 50 47 3 HS+FS+ OXC, LEV, CLB
E1017 Female 23 1 22 HS+FS+ LTG, TPM, CLB, OXC
E1213 Male 60 2 58 HS+FS+ CBZ, VPA, LTG, DZP
E1219 Male 36 9 27 HS+FS+ LEV, VPA, OXC
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room temperature for 20 min, sections were washed
three times in 1M tris-buffered saline (TBS) 5 min each.
After incubation in TBS containing 1% H2O2 for 30 min
at room temperature, slides were washed three times 5
min in respectively TBS-triton 0.3% (TBS-T), TBS, and
TBS-T. Sections were blocked for 30 min at room
temperature in TBS-T with 3% normal donkey serum
(NDS) before incubation with primary antibodies diluted
in TBS-T 0.3% NDS for overnight at 4 °C (rabbit anti-5-
hmC, Active Motive, 1:5000; mousse anti-5-mC, Genway
Biotech, 1:1000; rabbit anti-DNMT3a, sc-20703, Santa
Cruz, 1:500). Slides were washed three times 5 min in
TBS-T, TBS, and TBS-T at room temperature. Then,
sections were incubated for 1 h at room temperature
with secondary antibodies diluted in TBS-T 0.3% NDS
(biotinylated donkey anti-rabbit or anti-mouse, Jackson
ImmunoResearch, 1:200). After three washing in TBS-T,
TBS, and TBS-T (5 min each), slides were incubated for
2 h at room temperature with Vectastain ABC kit (Vec-
tor Laboratories) diluted 1:500 in TBS-T. Slides were
then washed two times in TBS and one time in Tris-HCl
0.05M (pH 7.6), and subsequently incubated in 3,3′-Di-
aminobenzidine (DAB)-Peroxidase Substrate solution
(0.05% DAB, 0.015% H2O2, Tris-HCl 0.025M, pH 7.6)
for 10 min and washed three times 5 min each in TBS at
room temperature. Slides were dehydrated and cover-
slipped using Pertex mounting medium (HistoLab). Pic-
tures were taken with an Olympus AX70 microscope
with bright field illumination coupled to a digital camera
(f-view, Olympus) as previously described [52].
In situ hybridization
Formalin-fixed paraffin-embedded tissues were cut at
5 μm on the microtome (Leica). Sections were trans-
ferred onto SuperFrost Plus slides (VWR) and dried
overnight at 37 °C. Slices were deparaffinized in xylene,
decreasing concentrations in ethanol solutions and PBS
at room temperature then treated with 15 μg/ml of Pro-
teinase K for 10min at 37 °C. Slides were incubated with
pre-hybridization solution (USBiological) for 3 h at 60 °C
and then hybridized with 40 nM double-DIG-LNA probe
(Exiqon) complementary to DNMT3a2 mRNA overnight
at 55 °C. Slides were washed in the following buffers for
10 min each at 55 °C: twice in 5× standard saline sodium
citrate (SSC), once in 2× SSC, three times in 5M tetra-
methylammonium chloride (TMAC), and twice in 2×
SSC. Treatment with 1 μg/ml Proteinase K in 2× SSC
was done for 30 min at 55 °C before another series of
washing steps of 5 min each: 2× SSC, 1× SSC, and 0.2×
SSC (all at 55 °C), two times in 0.2× SSC at 37 °C and
once in 0.2× SSC at room temperature. Slides were then
rinsed twice with PBS for 10min at room temperature,
blocked for 1 h in blocking solution (USBiological), and
incubated with anti-DIG alkaline phosphatase-conjugated
antibody overnight at 4 °C (USBiological). Tissues were
washed with Alkaline Phosphatase buffer twice for 5min
at room temperature and subsequently incubated in nitro-
blue tetrazolium/5-bromo-4-chloro-3indolyl phosphate
(NBT/BCIP) color substrate at room temperature in the
dark for 72 h. The slides were rinsed with water, cover-
slipped with aqua mount (Lerner Laboratory). Positive
controls and no-probe controls were included for each
hybridization procedure.
Microscopy and image analysis
For intensity measurements, images were taken with the
× 10 objective using a bright-field filter for each staining.
All images were taken using identical camera, micro-
scope lens, and light settings. One hippocampal/neocor-
tex section was used per each staining, where images
were taken from five sites in the DG per subject. All im-
ages for signal intensity analysis were taken with Olym-
pus AX70 Grey value microscope. ImageJ version 1.51j8
was used to calculate the integrated density of the stain-
ing. The threshold baseline was calculated by averaging
the thresholds of three randomly selected DG pictures
(beginning, middle, and end) from all the sections, both
control and TLE slides. The setting was as follows:
image was inverted, type was 32 bits, background pixel
was set to NaN, and set measurements were area, mean
gray value, standard deviation, min and max gray value,
and integrated density.
For stereology measurements, live image of DNMT3a,
5-mC, and 5-hmC stained slides were observed under
bright field using the stereology microscope Olympus
BX51. The configuration of the stereology microscope
Table 2 Clinical characteristics of TLE patients and post-mortem controls (Continued)
E1221 Female 41 4 37 HS+FS+ CLZ, CBZ
E1305 Female 20 1 19 HS+FS+ MDZ, LEV, TMP
E1310 Female 43 28 15 HS+FS+ LEV, LTG, CLB
E1314 Male 42 8 34 HS+FS+ LTG, CLB
E1408 Male 33 0 33 HS+FS+ CBZ, CLB, MDZ
E1416 Female 41 20 21 HS+FS+ LEV, LTG, CLB
CBZ carbamazepine, CLB clobazam, CLZ clonazepam, DZP diazepam, FLU flupentixol, FS febrile seizures, HS hippocampal sclerosis, LAC lascosamide, LEV
levotiracetam, LTG lamotrigine, MDZ midazolam, MET methotrimeprazine, OXC oxcarbazepine, PHT phenytoin, PMI post-mortem interval, TLE temporal lobe
epilepsy, TPM topiramate, VPA valproic acid, ZOP zopiclone, N/A not available
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consists of Olympus BX51, LEP MAC5000, and MBF
CX9000 camera. The DG expressing the desired probe
was manually drawn using StereoInvestigator program at
× 10 magnification. The software automatically quanti-
fied the area (μm2) with its corresponding coefficient of
error (CE).
Murin post-mortem interval
NMRI mice were killed by cervical dislocation. Hippocam-
pus and temporal neocortex tissues were collected either
immediately after death or following a 1, 8, 16, or 24 h
delay at room temperature. Tissue samples were dissected
in PBS at 4 °C, immediately frozen on dry ice and stored
at − 80 °C. Mice were provided by the GIGA-neuroscience
department of the University of Liège. They were used for
another study involving embryonic research. They were
treated according to the guidelines of Belgian Ministry of
Agriculture in agreement with European Community La-
boratory Animal Care and Use Regulations.
Statistics
Statistical analyses were carried out using RStudio (version
1.2.1335), and graphs were built using GraphPad Prism
software (version 5.0a). Values are either presented as mean
and standard error of the mean or presented as mean and
coefficient of error (Stereology). The normal distribution of
the data was proved using the Shapiro-Wilk test. The one-
way ANOVA followed by Bonferroni post hoc was used to
test for multiple comparisons between groups. Age and
gender have been used as confounding factors in the ana-
lyses. Correlation analyses were done by calculating the
Pearson’s correlation coefficient. Differences between the
groups were considered significant for p ≤ 0.05. During ex-
periments, the experimenter was blinded to the experimen-
tal condition to prevent biased assessment. Cohen’s d effect
size was used to perform two-tail post hoc power analysis
using G*Power software (version 3.1.9.4) [54]. A summary
of the statistical analysis is provided in Additional file 6.
Additional files
Additional file 1: GAPDH expression levels in Western blots analysis.
Quantification of the expression levels of GAPDH in the Western blots
analyzing DNMT1 (A, B) and DNMT3a (C, D) in the hippocampus and the
neocortex. (PDF 1126 kb)
Additional file 2: Effect of post-mortem interval on murine Dnmt1
expression. (A, C) Representative Western blots of Dnmt1 (green) in the
mouse hippocampus (A) and neocortex (C) extracted immediately (0 h)
or after 1, 8, 16, or 24 h delay at room temperature. Gapdh (red) was
used as a protein loading control. (B, D) Graph showing semi-
quantification of the Western blots (n = 2 per time point) for the
hippocampus (B) and neocortex (D). Data are presented as relative
expression normalized to Gapdh. Error bars show SEM. MM: molecular
weight marker. (PDF 3164 kb)
Additional file 3: Effect of post-mortem interval on murine Dnmt3a
isoforms expression. (A, C) Representative Western blots of the various
Dnmt3a isoforms (green) in the mouse hippocampus (A) and neocortex
(C) extracted immediately (0 h) or after 1, 8, 16 or 24 h delay at room
temperature. Gapdh (red) was used as a protein loading control. (B, D)
Graph showing semi-quantification of the Western blots (n = 2 per time
point) for the hippocampus (B) and neocortex (D). Data are presented as
relative expression normalized to Gapdh. Error bars show SEM. MM:
molecular weight marker. (PDF 2061 kb)
Additional file 4: Detailed description of the clinical characteristics of
TLE patients and post-mortem controls. (XLSX 43 kb)
Additional file 5: Sequences of the qPCR primers. (XLSX 35 kb)
Additional file 6: Summary of the statistics. (XLSX 37 kb)
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